BTI's smokeless pivot battles illicit pressure
- BTI still depends on combustibles, which produced £20,201 million of 2025 revenue.
- Smokeless products now represent 19.8% of group revenue, growing 160 basis points over the last year.
- Velo is a major growth engine, expanding with the new Velo Max launch in the U.S.
- Vuse is under pressure because BTI estimates illegal flavoured vapour is 70% of the U.S. vapour market.
- The core question is whether smokeless growth can offset falling cigarette volumes before regulation or illicit trade blocks the path.
A cash machine trying to shrink smoking
BTI is trying to move smokers from cigarettes into smokeless products. That means vapour, nicotine pouches, heated tobacco, and oral tobacco. The bull case is simple: the cigarette business keeps throwing off cash while Vuse, Velo, glo, and other smokeless brands grow large enough to take over.
The shift is making progress. Smokeless products now represent 19.8% of group revenue. State enforcement and new FDA prioritization guidance are clearing a path for legal vapour and pouch growth, including the U.S. launch of Velo Max and the reintroduction of Vuse flavors.
The bear case is that the bridge breaks. The FDA can slow or reject new U.S. smokeless products. Consumers may choose illegal or cheaper products instead of BTI brands. BTI also says illegal flavoured and single-use vapour products make up 70% of the total U.S. vapour market. That is a direct hit to legal Vuse sales.
The biggest watch items are FDA decisions, enforcement against illegal vapour, and global cigarette volume declines. A sudden excise tax hike in Brazil shows how quickly combustible revenues can be disrupted by policy changes.
Cigarette cash funds the pivot
BTI makes money by selling nicotine products through a global brand and distribution system. The largest pool is combustibles, mostly cigarettes. Price increases help offset lower cigarette volumes, but regional shocks like Brazil's recent excise tax hike can disrupt this cash flow.
The future plan is called Building a Smokeless World. In plain English, BTI wants more of its sales to come from products that do not burn tobacco. These products are still addictive, and in the U.S. BTI says no reduced-risk claims can be made for Vuse, Velo, Grizzly, Kodiak, or Camel Snus without FDA clearance.
The model works if cigarette cash lasts long enough and smokeless products become large, profitable, and legal. It breaks if regulators block the products, if illegal competitors keep taking share, or if consumers do not switch at the price BTI needs.
From cigarettes to pouches
Combustible cigarettes
This is still the profit engine. Revenue was £20,201 million in 2025, but group cigarette volume fell 7.9%.
Vuse vapour
Vuse is BTI's main vapour brand. New state enforcement and FDA guidance are paving the way for Vuse flavors to return, though illicit competitors remain a huge threat.
Velo Modern Oral
Velo nicotine pouches are the strongest growth line. Modern Oral is expanding further with the Q3 launch of Velo Max in the U.S. across new strengths and flavors.
glo heated products
glo heats tobacco instead of burning it. Heated products revenue was £914 million in 2025, slightly lower as reported.
Grizzly, Kodiak, and Camel Snus
These are U.S. oral tobacco brands. Traditional Oral revenue fell 4.5% in 2025 as some users moved toward Modern Oral.
Beyond Nicotine
BTI invests in areas such as wellness and cannabis-related opportunities. These remain small compared with tobacco and nicotine.
Where the revenue comes from
The mix below uses BTI's 2025 reported revenue by filing segment. The U.S. is the largest region, while product economics still depend heavily on combustibles.
What could break the pivot
FDA approvals stall
High impact · Medium oddsBTI's U.S. smokeless products, including Vuse and Velo, are subject to FDA regulation. If the FDA rejects key products or delays new variants, BTI loses room to refresh the portfolio. That would make the smokeless transition slower and more expensive.
Illegal vapour keeps winning
High impact · High oddsBTI estimates illegal flavoured and single-use vapour products are 70% of the total U.S. vapour market. These products can be cheaper, sweeter, or more available than legal products. That can cap Vuse growth even when consumer demand for vapour exists.
Combustible decline outruns price
High impact · Medium oddsCigarettes still fund the company. Group cigarette volume fell 7.9% in 2025, while combustibles revenue fell 2.3% as reported. If volume declines speed up and price increases stop covering the gap, cash for dividends and the transition could tighten.
Generational sales bans spread
Medium impact · Medium oddsA generational sales ban would permanently block sales of tobacco products to people born after a set year. BTI flagged the UK, the Maldives, and other countries as places where this idea has moved forward or is being studied. These rules would not hit all revenue at once, but they could shrink the long-term cigarette base.
Excise tax shocks hit volume
Medium impact · High oddsSudden changes to tax policy can disrupt combustible sales. A recent excise tax shock in Brazil created immediate headwinds for cigarette volumes. These localized shocks can drag down regional performance.
In one breath
Is British American Tobacco only a cigarette company?
No. Cigarettes are still the largest revenue source, but BTI is building vapour, heated tobacco, nicotine pouch, and oral tobacco brands. The key question is whether those smokeless products can become big enough before cigarette volumes fall too far.
Why does the FDA matter so much for BTI?
The FDA controls which tobacco and nicotine products can be legally sold in the U.S. BTI's U.S. products, including Vuse and Velo, need to fit FDA rules. Approvals can help growth, while rejections or delays can block launches.
What is the biggest risk to Vuse?
Illicit vapour is the clearest risk. BTI estimates illegal flavoured and single-use vapour products are 70% of the total U.S. vapour market. That gives unapproved products a large share of the market Vuse wants to serve.
What should investors watch next?
Watch FDA decisions, enforcement against illegal vapour, New Categories revenue growth, and cigarette volume declines. Those signals show whether BTI's smokeless shift is working or stalling.
